Technology research and development company MuMac — which is also a spin-off company of the University of Manchester in the U.K. — is working to raise funds to commercialize its RapiDA test for early-stage age-related macular degeneration (AMD).
According to MuMac, the RapiDA can detect early-stage AMD often before any obvious biological changes can be detected with imaging devices. The small, patented device is reportedly user-friendly and can perform a screening and identify early-age AMD in five to 10 minutes.
MuMac reportedly plans to use any raised finances to finish the design of the RapiDA for manufacturing, followed by marketing and selling of the product to end users. Additionally, MuMac is reportedly working on other eye testing instruments in its R&D pipeline.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
Source: University of Manchester